SCHEMBL13699132

SCHEMBL13699132

CCOc1cc(NC(=O)NC(CC)CC)ccc1Oc1ccc(N(CC)C(=O)c2ccc(OC3CC4CCC(C3)N4C)cc2)cc1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.35
ACACB O00763 1/20 0.34
OPRK1 P41145 1/20 0.34
ALDH1A1 P00352 3/20 0.33
TAS1R3 Q7RTX0 2/20 0.33
TAS1R1 Q7RTX1 2/20 0.33
KDM4E B2RXH2 2/20 0.33
HPGD P15428 2/20 0.33
MCHR1 Q99705 1/20 0.33
MAPT P10636 2/20 0.33
QPCT Q16769 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
LPAR1 Q92633 1/20 0.33
LPAR5 Q9H1C0 1/20 0.33
CYP3A4 P08684 1/20 0.32
TTK P33981 1/20 0.32
AURKB Q96GD4 1/20 0.32
INCENP Q9NQS7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13699221 0.93 CYP2D6 (0.40) PKMALDH1A1TAS1R3TAS1R1MCHR1
SCHEMBL13699233 0.91 ALDH1A1 (0.37) PKMACACBOPRK1ALDH1A1MAPT
SCHEMBL13699150 0.88 PKM (0.40) PKMALDH1A1TAS1R3TAS1R1KDM4E
SCHEMBL13699331 0.88 CHRM1 (0.39) PKMTAS1R3TAS1R1MCHR1MAPT
SCHEMBL13699168 0.86 PKM (0.39) PKMOPRK1ALDH1A1TAS1R3TAS1R1
SCHEMBL13699295 0.86 CYP2D6 (0.37) PKMALDH1A1TAS1R3TAS1R1MCHR1
SCHEMBL13699207 0.86 PKM (0.41) PKMOPRK1ALDH1A1TAS1R3TAS1R1
SCHEMBL4239122 0.82 PKM (0.33) PKMALDH1A1TAS1R3TAS1R1KDM4E
SCHEMBL13699277 0.81 PKM (0.45) PKMALDH1A1TAS1R3TAS1R1MCHR1
SCHEMBL4237691 0.81 SMN1; SMN2 (0.43) PKMALDH1A1TAS1R3TAS1R1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885ACACB 2790/4885OPRK1 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.